stockrow
Wednesday 4 November 2026
Export ALT’s income statement to Excel — free account
Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024.
- Revenue
- +520.0%
- EPS
- +55.6%
- Free cash flow
- −25.3%
- Total debt
- +142.4%
Quarter to June 2026, against a year earlier
2.10
0.06
+2.94%
Follow ALT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 3 | 11 | 10 | 6 | 8 | 4 | 0 | 0 | 0 | 0 | 0 | (38.5%) | 3 | 3 | 3 | +296.8% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | (11) | (52) | (45) | (21) | (54) | (97) | (85) | (88) | (95) | (89) | (92) | +26.0% | ||||||
| EBT margin, % | (342.59) | (484.84) | (438.68) | (354.72) | (665.38) | (2,201.59) | 124,867.65 | (20,762.21) | (475,295.00) | (216,521.95) | 0.00 | (216,179.4) pt | ||||||
| Net income | (11) | (46) | (39) | (21) | (49) | (97) | (85) | (88) | (95) | (88) | (92) | +25.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 14.06 | 24.86 | 3.69 | 0.44 | 0.32 | 0.11 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | (68.0%) | |||||
| Earnings | (48.17) | (120.42) | (15.16) | (1.60) | (1.91) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) | (0.78) | (35.0%) | ||||||
| Cash flow | (27.60) | (46.80) | (3.35) | (0.73) | (1.34) | (1.90) | (1.33) | (1.42) | (1.12) | (0.77) | (0.41) | (32.8%) | ||||||
| Capex | (0.96) | (0.37) | (0.36) | 0.00 | (0.01) | (0.30) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (63.9%) | ||||||
| Free cash flow | (28.56) | (47.17) | (3.71) | (0.73) | (1.35) | (2.19) | (1.34) | (1.42) | (1.12) | (0.77) | (0.41) | (33.1%) | ||||||
| Book value | 139.91 | 91.22 | 17.24 | 3.47 | 8.81 | 4.82 | 3.95 | 3.65 | 1.74 | 2.55 | 2.56 | (35.9%) | ||||||
| Shares, m | 0 | 0 | 3 | 13 | 26 | 41 | 47 | 53 | 71 | 88 | 122 | +93.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 70.43 | 2.41 | 0.56 | 4.28 | 35.33 | 85.75 | 0.00 | 1,314.92 | 25,596.73 | 6,914.26 | 8,224.03 | 3,402.5 | ||||||
| P/B | 7.08 | 0.66 | 0.12 | 0.55 | 1.28 | 1.90 | 3.96 | 2.89 | 4.15 | 1.41 | 0.80 | 2.4 | ||||||
| EV/Sales | 69.62 | 1.32 | (2.69) | (1.86) | 9.15 | 42.88 | (8,079.20) | 851.59 | 19,023.93 | 1,717.80 | 1,889.09 | 1,363.3 | ||||||
| EV/FCF | (34.78) | (0.70) | 2.68 | 1.12 | (2.16) | (2.09) | (8.73) | (4.77) | (4.75) | (1.17) | (1.13) | (5.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (20) | (9) | (10) | (34) | (78) | (63) | (76) | (80) | (68) | (77) | +30.0% | |||||
| Capex | 0 | 0 | (1) | 0 | 0 | (12) | 0 | 0 | — | 0 | 0 | (28.3%) | ||||||
| Free cash flow | (7) | (20) | (10) | (10) | (35) | (91) | (63) | (76) | (80) | (68) | (77) | +29.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (1) | 20 | 35 | 35 | 218 | 186 | 176 | 197 | 127 | 263 | 322 | n/m | |||||
| Net debt | (3) | (12) | (34) | (36) | (214) | (189) | (184) | (198) | (132) | (239) | (292) | +63.5% | ||||||
| Shareholders’ equity | 32 | 39 | 48 | 46 | 226 | 199 | 185 | 194 | 124 | 225 | 474 | +24.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (39.32) | (101.26) | (72.13) | (38.55) | (32.79) | (41.85) | (39.79) | (42.36) | (54.33) | (42.03) | (25.58) | (2.7) pt | |||||
| ROIC | (23.62) | (120.07) | (185.13) | (131.45) | (300.78) | (610.37) | (5,217.65) | 0.00 | 0.00 | 0.00 | (34.30) | +23.6 pt | ||||||
| ROE | (46.90) | (143.46) | (96.86) | (44.70) | (36.14) | (45.69) | (44.07) | (46.63) | (59.86) | (50.57) | (28.87) | (3.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 13 | 30 | 27 | 25 | 43 | 47 | 52 | 59 | 59 | 57 | — | +17.8% | |||||
| Revenue/emp, $m | 0.25 | 0.36 | 0.38 | 0.23 | 0.19 | 0.09 | 0.00 | 0.01 | 0.00 | 0.00 | — | (47.8%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025
Altimmune, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics, Inc. | $455.5M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ASMB Assembly Biosciences, Inc. | $405.6M | — (loss-making) | — (loss-making) | +38.94% (above 0%: growing) | n/m | +7.58% (above 0%: growing) | 100.00% | (47.44%) | Compare |
| EDIT Editas Medicine, Inc. | $399.3M | — (loss-making) | — (loss-making) | +232.31% (above 0%: growing) | n/m | +40.72% (above 0%: growing) | 100.00% | (156.05%) | Compare |
| ALT Altimmune, Inc. | $396.8M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | |
| CCCC C4 Therapeutics, Inc. | $394.9M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | +86.84% (above 0%: growing) | 100.00% | (397.88%) | Compare |
| BLSM BlossomHill Therapeutics, Inc. | $394.5M | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| AVTX Avalo Therapeutics, Inc. | $388.8M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| ZURA Zura Bio Limited | $384.3M | — (loss-making) | — | — | n/m | −26.22% (below 0%: shrinking) | — | 0.00% | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $376.6M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| Median of peers | $394.7M | — | — | +38.94% | — | +40.72% | 77.87% | (23.72%) |
Pay and ownership Proxy statement filed 17 March 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 8.03m | 1.79m | 21.95 |
| 2024 | 6.09m | 2.45m | 78.71 |
| 2023 | 5.48m | 2.11m | 122.82 |
Ownership
Directors and executive officers, together
1.60%
The Vanguard Group
7.30%
Alyeska Master Fund, L.P.
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement